Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors

Molecular Psychiatry

Volumn 3, Issue 2, 1998, Pages 123-134

  Seeman, P ^a,b,c   Tallerico, T ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Family and Community Medicine Psychiatry Pharmacology   (Canada)

Author keywords

Antipsychotics; Atypical neuroleptics; Clozapine; D2 receptor occupancy; Risperidone

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; FLUPHENAZINE; HALOPERIDOL; MELPERONE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERLAPINE; QUETIAPINE; RACLOPRIDE; RADIOLIGAND; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; SULPIRIDE; TRIFLUOPERAZINE;

ARTICLE; CORPUS STRIATUM; DISSOCIATION CONSTANT; DRUG RECEPTOR BINDING; LIMBIC CORTEX; PARKINSONISM; PRIORITY JOURNAL;

EID: 0031953450     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000336     Document Type: Article

References (101)

1. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 1992; 49: 538-544.
2. 2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995; 152: 1444-1449.
3. 2 dopamine receptor occupancy and plasma antipsychotic drug levels in man. Int Clin Psychopharmacology 1995; 10 (Suppl 3): 81-85.
4. 2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 1995; 57: PL103-PL107.
5. 2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 1996; 153: 948-950.
6. 2 receptor occupancy profile of loxapine determined using PET. Neuropsychopharmacology 1996; 15: 562-566.
7. Knable MB, Heinz A, Coppola R, Gorey J, Weinberger DR. IBZM SPECT measurement of D2 receptor occupancy by haloperidol and risperidone. (Abstract) Biol Psychiatry 1996; 39: 515.
8. 2 dopamine receptor binding differences of clozapine and haloperidol. J Neural Transm 1991; 86: 163-173.
9. 18FESP. In: Brunello N, Mendlewicz J, Racagni G (eds). New Generation of Antipsychotic Drugs: Novel Mechanisms of Action, vol 4. Int Acad Biomed Drug Res, Basel, Karger, 1993, pp 130-135.
10. 2-receptor-antagonism by antipsychotics in man. (Abstract) Schizophrenia Res 1996; 18: 141.
11. 11C NMSP receptor occupancy by clozapine and haloperidol in schizophrenic subjects. (Abstract) Schizophrenia Res 1995; 15: 80.
12. 11C NMSP receptor occupancy by clozapine and haloperidol in schizophrenic subjects. (Abstract) Biol Psychiatry 1996; 39: 513.
13. Kapur S. SDA antipsychotics: from theory to clinical practice. Lessons from PET neuroimaging. (Abstract) 20th Collegium Int Neuropsychopharmacol 1996; S-17-3.
14. 123I-IBZM single photon emission tomography (SPET) study. Psychopharmacology 1995; 117: 55-61.
15. 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology 1996; 124: 148-153.
16. 2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics. Am J Psychiatry 1996; 153: 183-190.
17. Su T-P, Breier A, Coppola R, Hadd K, Elman I, Adler C et al. D2 receptor occupancy in risperidone and clozapine-treated schizophrenics. Biol Psychiatry 1996; 39: 512-513.
18. Su T-P, Breier A, Coppola R, Hadd K, Elman I, Alder C et al. D2 receptor occupancy during risperidone and clozapine treatment in chronic schizophrenia: relationship to blood level, efficacy and EPS. (Abstract) Soc Neurosci Abstr 1996; 22: 265.
19. 2 dopamine receptor occupancy in clozapine-treated patients. Am J Psychiatry 1996; 153: 1571-1578.
20. Brunello N, Masotto C, Steardo L, Markstein R, Racagni G. New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 1995; 13: 177-213.
21. 4 receptor varies with the affinity of the competing radioligand. Eur J Pharmacol - Mol Pharmacol Section 1995; 291: 59-66.
22. 3 receptors. Mol Pharmacol 1993; 43: 749-754.
23. Seeman P. Therapeutic receptor-blocking concentrations of neuroleptics. Int Clin Psychopharmacol 1995; 10 (Suppl 3): 5-13.
24. Seeman P, Corbett R, Van Tol HHM. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4. Neuropsychopharmacology 1996; 16: 91-110.
25. Seeman P, Corbett R, Nam D, Van Tol HHM. Dopamine and serotonin receptors: amino acid sequences, and clinical role in neuroleptic Parkinsonism. Jpn J Pharmacol 1996; 71: 187-204.
26. Seeman P, Kapur S. Clozapine occupies high levels of dopamine D2 receptors. Life Sci 1997; 60: 207-216.
27. Seeman P. Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2, clozapine occupies D4. Neuropsychopharmacology 1992; 7: 261-284.
28. 3H-spiperone depend on tissue concentration: analysis and examples. J Neurochem 1984; 43: 221-235.
29. Seeman P, Wong M, Lee T. Dopamine receptor-block and nigral fiber-impulse blockade by major tranquilizers. (Abstract) Fed Proc 1974; 33: 246.
30. Seeman P, Chau-Wong M, Tedesco J, Wong K. Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci USA 1975; 72: 4376-4380.
31. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717-719.
32. 3H]dopamine binding associated with dopamine receptors in calf brain membranes. Mol Pharmacol 1976; 12: 800-812.
33. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975; 188: 1217-1219.
34. Seeman P, Lee T. Neuroleptic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. In: Sedvall G (ed). Antipsychotic Drugs. Pharmacodynamics and Pharmacokinetics. Karolinska Institute, Pergamon: Oxford, 1976, pp 183-191.
35. Parson LH, Justice Jr JB. Extracellular concentration and in vivo recovery of dopamine in the nucleus accumbens using microdialysis. J Neurochem 1992; 58: 212-218.
36. Kawagoe KT, Garris PA, Wiedemann DJ, Wightman RM. Regulation of transient dopamine concentration gradients in the microenvironment surrounding nerve terminals in the rat striatum. Neuroscience 1992; 51: 55-64.
37. Laruelle M, De Souza C, Baldwin RM, Abi-Dargham A, Bowers M, Seibyl JP et al. SPECT measurement of human striatal synaptic dopamine concentration in the resting state. (Abstract) Soc Neurosci Abstr 1996; 22: 266.
38. George SR, Watanabe M, Di Paolo T, Falardeau P, Labrie F, Seeman P. The functional state of the dopamine receptor in the anterior pituitary is in the high-affinity form. Endocrinology 1985; 117: 690-697.
39. 3) as a target for neuroleptics. Nature 1990; 347: 146-151.
40. 3 dopamine receptors to G-proteins. FEBS Lett 1993; 315: 223-226.
41. 1 receptor pharmacology. ISI Atlas of Sci Pharmacol 1988; 2: 161-170.
42. Chio CL, Lajiness ME, Huff RM. Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol Pharmacol 1994; 45: 51-60.
43. 2 dopamine receptor isoforms. Nature 1989; 342: 923-926.
44. 3 receptors: effects of ions and guanine nucleotides. J Pharmacol Exper Ther 1995; 274: 790-797.
45. 2 receptor binding sites for agonists. Mol Pharmacol 1985; 28: 391-399.
46. Nordin C, Almé B, Bondesson U. CSF and serum concentrations of clozapine and its demethyl metabolite: a pilot study. Psychopharmacology 1995; 122: 104-107.
47. Szymanski S, Lieberman J, Pollack S, Munne R, Safferman A, Kane J et al. The dopamine-serotonin relationship in clozapine response. Psychopharmacology 1993; 112: S85-S89.
48. Lieberman J, Johns C, Pollack S, Masiar S, Bookstein P, Cooper T et al. Biochemical effects of clozapine in cerebrospinal fluid of patients with schizophrenia. In: Tamminga CA, Schultz SC (eds). Advances in Neuropsychiatry and Psychopharmacology, Volume 1: Schizophrenia Research. Raven Press: New York, 1991, pp 341-349.
49. Meltzer HY, Kennedy J, Dai J, Parsa M, Riley D. Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. A high potency effect of clozapine. Neuropsychopharmacology 1995; 12: 39-45.
50. Hagesawa M, Gutierrez-Esteinou R, Way L, Meltzer HY. Relationship between clinical efficacy and clozapine concentration in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 1993; 13: 383-390.
51. Oleson OV, Thomsen K, Jensen PN, Wulff CH, Rasmussen N-A, Refshammer C et al. Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross-sectional study. Psychopharmacology 1995; 117: 371-378.
52. Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991; 148: 231-235.
53. Lin S-K, Chang W-H, Chung M-C, Lam F, Jann MW. Disposition of clozapine and desmothylclozapine in schizophrenic patients. J Clin Pharmacol 1994; 34: 318-324.
54. Haring C, Fleischhacker WW, Schett P, Humpel C, Barnas C, Saria A. Influence of patient-related variables on clozapine plasma levels. Am J Psychiat 1990; 147: 1471-1475.
55. Olesen OV, Poulsen B. On-line fully automated determination of clozapine and desmethylclozapine in human serum by solid-phase extraction on exchangeable cartridges and liquid chromatography using a methanol buffer mobile phase on unmodified silica. J Chromatog 1993; 622: 39-46.
56. Casey DE. Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates. Psychopharmacology 1993; 112: S55-S59.
57. 2 receptor occupancy induced by risperidone in schizophrenic patients. (Abstract) Am College Neuropsychopharmacol 1996; 35: 184.
58. 2 receptor blocking agent, ritanserin, in the rat. Eur Neuropsychopharmacol 1996; 6: 305-310.
59. 2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release. Psychopharmacology 1997; 131: 57-63.
60. Farde L, Nyberg S, Nordström A-L, Halldin C, Sedvall G. Dopamine and serotonin receptor occupancy examined by PET in antipsychotic drug treated patients. (Abstract) Am College Neuropsychopharmacol 1993; 32: 38.
61. 2 receptor occupancy studies and clinical response. Br J Psychiatry 1996; 168: 40-44.
62. 2A antagonist with a favorable CNS safety profile. J Pharmacol Exper Ther 1996; 277: 968-981.
63. Labrecque J, Fargin A, Bouvier M, Chidiac P, Dennis M. Serotonergic antagonists differentially inhibit spontaneous activity and decrease ligand binding capacity of the rat 5-hydroxytryptamine type 2C receptor in Sf9 cells. Mol Pharmacol 1995; 48: 150-159.
64. 1C receptors. J Pharmacol Exper Ther 1992; 260: 1361-1365.
65. 1C receptor antagonists. Eur J Pharmacol - Mol Pharmacol Sect 1993; 245: 179-182.
66. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, et al. VII. International Union of Pharmacology Classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994; 46: 157-203.
67. 3H]raclopride: implications for positron emission tomography of the human brain. Synapse 1989; 3: 96-97.
68. 11C-raclopride and positron emission tomography. J Neurosci 1992; 12: 3773-3780.
69. Gifford AN, Gatley SJ, Ashby Jr CH. Endogenouslv released dopamine inhibits the binding of dopaminergic PET and SPECT ligands in supervised rat striatal slices. Synapse 1996; 22: 232-238.
70. Laruelle M, Abi-Dargham A, Gil R, Van Dyck CH, Erdos J, D'Souza D et al. SPECT imaging of synaptic dopamine release in drug free schizophrenic patients: an experimental validation of the dopamine hypothesis of schizophrenia. Schizophrenia Res 1996; 18: 198-199.
71. Kalkman HO, Neumann V, Tricklebank MD. Clozapine inhibits catalepsy induced by olanzapine and loxapine, but prolongs catalepsy induced by SCH 23390 in rats. Naunyn-Schmiedeberg's Arch Pharmacol 1997; 355: 361-364.
72. Wong DF, Gjedde A, Wagner Jr HN, Dannals RF, Douglass KH, Links JM et al. Quantification of neuroreceptors in the living human brain. II. Inhibition studies of receptor density and affinity. J Cereb Blood Flow Metab 1986; 6: 147-153.
73. Murphy RA, Kung HF, Kung M-P, Billings J. Synthesis and characterization of iodobenzamide analogues: potential D-2 dopamine receptor imaging agents. J Med Chem 1990; 33: 171-178.
74. 123I]IBZM) in rat and human brain. Nucl Med Biol 1991; 18: 837-846.
75. Gatley SJ, Volkow ND, Gifford AN, Ding Y-S, Logan J, Wang G-J. Model for estimating dopamine transporter occupancy and subsequent increases in synaptic dopamine using positron emission tomography and carbon-11-labeled cocaine. Biochem Pharmacol 1997; 53: 43-52.
76. 3H]Cocaine binding sites in caudate-putamen. J Pharmacol Exper Ther 1989; 251: 131-141.
77. 125I]RTI-55 to dopamine and serotonin transporters in rat brain. Synapse 1992; 12: 27-36.
78. 2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients. Biol Psychiatry 1991; 29: 629-634.
79. 2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 1992; 340: 199-202; correction, 340: 380.
80. 123I-IBZM SPET (single photon emission tomography) study. Psychol Med 1993; 23: 791-797.
81. Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue C-Y et al. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 1989; 146: 905-908.
82. Kane J, Honigfeld G, Singer J, Meltzer HY, Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796.
83. Scurlock HJ, Robinson PH. Case report 2: remoxipride in resistant schizophrenia. J Drug Dev 1993; 6: 71-72.
84. Scurlock HJ, Singh AN, Catalan J. Atypical antipsychotic drugs in the treatment of manic syndromes in patients with V-1 infection. J Psychopharmacol 1995; 9: 151-154.
85. Vartianen H, Leinonen E, Putkonen A, Lang S, Hagert U, Tolvanen U. A long-term study of remoxipride in chronic schizophrenic patients. Acta Pschiatr Scand 1993; 87: 1134-117.
86. Shore D, Matthews S, Cott J, Lieberman JA. Clinical implications of clozapine discontinuation: report of an NIMH workshop. Schizophrenia Bull 1995; 21: 333-338.
87. Meltzer HY, Lee MA, Ranjan R, Mason EA, Cola PA. Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine. Psychopharmacology 1996; 124: 176-187.
88. 2 occupancy and dopamine release determined by 123I-IBZM SPECT following clozapine dose reduction. (Abstract) Schizophrenia Res 1995; 15: 96.
89. Baron JC, Martinot JL, Cambon H, Boulenger JP, Poirier MF, Caillard V et al. Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology 1989; 99: 463-472.
90. Tauscher J, Kufferle B, Neumeister A, Asenbaum S, Brucke T, Podreka I et al. IBZM-SPECT shows low striatal D2 blockade under therapy with seroquel. (Abstract) Biol Psychiatry 1996; 39: 513.
91. Kasper S, Tauscher J, Küfferle B, Asenbaum S, Barnas C, Hesselman B et al. Sertindole and dopamine D2 occupancy. (Abstract) Am College Neuropsychpharmacol 1996; 35: 265.
92. 2 receptor occupancy of ziprasidone in healthy volunteers. (Abstract) Am College Neuropsychopharmacol 1996; 35: 269.
93. Friedman JH, Lannon MC. Clozapine in the treatment of psychosis in Parkinson's disease. Neurology 1989; 39: 1219-1221.
94. Pfeiffer RF, Kang J, Graver B, Hofman R, Wilson J. Clozapine for psychosis in Parkinson's disease. Movement Disorders 1990; 5: 239-242.
95. Kahn N, Freeman A, Juncos JL, Manning D, Watts RL. Clozapine is beneficial for psychosis in Parkinson's disease. Neurology 1991; 41: 1699-1700.
96. Factor SA, Brown D. Clozapine prevents recurrence of psychosis in Parkinson's disease. Movement Disorders 1992; 7: 125-131.
97. Rabey JM, Treves TA, Neufeld MY, Orlov E, Korczyn AD. Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology 1995; 45: 432-434.
98. Sandor P, Lang AE, Singal S, Angus C. Remoxipride in the treatment of levodopa-induced psychosis. J Clin Psychopharmacol 1996; 16: 395-399.
99. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991; 41: 1-24.
100. Casey DE. Will the new antipsychotics bring hope of reducing the risk of developing extrapyramidal syndromes and tardive dyskinesia? Int Clin Psychopharmacol 1997; 12: (suppl 1): S19-S27.
101. Seeman P. Tardive dyskinesia, dopamine receptors, and neuroleptic damage to cell membranes. J Clin Psychopharmacol 1988; 8: 3S-9S.